- Conditions
- Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
- Interventions
- Itolizumab, EQ001 Placebo
- Biological · Drug
- Lead sponsor
- Equillium
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Moderate to Severe Chronic Plaque Psoriasis
- Interventions
- Stelara, Bmab1200
- Biological
- Lead sponsor
- Biocon Biologics UK Ltd
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Mayfield Heights, Ohio
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Acute-graft-versus-host Disease, aGVHD, GVHD, GVHD, Acute
- Interventions
- EQ001, EQ001 Placebo
- Biological
- Lead sponsor
- Biocon Limited
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 16
- States / cities
- Duarte, California • Gainesville, Florida • Miami, Florida + 13 more
- Conditions
- Lupus Erythematosus, Lupus Nephritis
- Interventions
- Itolizumab [Bmab 600]
- Drug
- Lead sponsor
- Biocon Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 19
- States / cities
- Sun City, Arizona • Chula Vista, California • La Jolla, California + 14 more
- Conditions
- Healthy Volunteers
- Interventions
- Bmab 1000, Prolia®
- Biological
- Lead sponsor
- Biocon Biologics UK Ltd
- Industry
- Eligibility
- 28 Years to 55 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Newark, New Jersey